Drug intelligence / Profile preview

Alevicyn SG

Development stage
Unknown
Lead developer
Sonoma Pharmaceuticals
Modality
Small Molecules
Administration
Topical
01

Overview

Alevicyn SG is a prescription topical dermatological spray gel developed by Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) using its proprietary Microcyn Technology. The product's active ingredient is hypochlorous acid (HOCl), a naturally occurring molecule used by the immune system to combat pathogens. Alevicyn SG is FDA-cleared for the management and relief of burning, itching, and pain associated with various dermatoses, including atopic dermatitis (eczema) and radiation dermatitis. It is also indicated for the care of first- and second-degree burns and for pre- and post-procedure skin management, such as in skin cancer procedures. As a non-steroidal and non-antibiotic alternative, it helps maintain a moist wound environment and possesses broad-spectrum antimicrobial activity against clinically relevant organisms.

Brand names
Alevicyn SGAlevicyn SG Antipruritic Spray Gel
Other names
hypochlorous acid
02

Targets

Streptococcus mutans cytoplasmic membrane

Beyond the preview

Go deeper on Alevicyn SG.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alevicyn SG.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call